Pershing Edward bought PVCT
July 18, 2025 · Form 4 insider transaction
Pershing Edward bought 62,303 shares of Provectus Biopharmaceuticals, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 3 days after the transaction.
Direction
Acquired (buy-side)
Shares
62,303
Price
$0.00
Total value
N/A
InsiderPershing Edward
Role—
SecuritySeries D-1 Convertible Preferred Stock
Transaction codeM: Option exercise
Transaction dateJuly 18, 2025
Filing dateJuly 21, 2025
Shares owned after2,295,727
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").; The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.